Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $35.00.

Douglas Tsao has given his Buy rating due to a combination of factors that highlight Immunovant’s promising future prospects. The company is advancing its IMVT-1402 program across multiple indications, including Graves’ Disease and Sjögren’s disease, with potential registrational studies set to begin in the summer of 2025. This strategic focus under new management is supported by a strong cash position of $714 million, which is expected to sustain operations through the anticipated readout in 2027.
Additionally, IMVT-1402’s unique position as the only FcRn under development for the GD indication, coupled with its potential to significantly reduce IgG levels, suggests substantial clinical benefits for patients. The company’s innovative approach in offering an autoinjector delivery method for myasthenia gravis is also seen as a key differentiator, providing convenience and flexibility for patients. Despite financial losses reported in 4Q25, the company’s robust cash reserves and strategic advancements underpin Tsao’s positive outlook and the adjusted price target of $35.

Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, scPharmaceuticals, and Neumora Therapeutics, Inc.. According to TipRanks, Tsao has an average return of 7.5% and a 38.06% success rate on recommended stocks.

In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.